NRAV promotes HCC stemness via the m6A-regulated let-7c-5p/LIN28B axis
10.0
来源：
Nature
关键字：
mRNA
发布时间：
2025-12-13 03:39
摘要：
NRAV is identified as an m6A-modified long non-coding RNA that promotes stemness in hepatocellular carcinoma (HCC) through the let-7c-5p/LIN28B axis. The study demonstrates that NRAV enhances the expression of cancer stem cell markers and correlates with poor prognosis in HCC patients. By acting as a competing endogenous RNA, NRAV stabilizes LIN28B expression, linking RNA modifications to cancer stemness. This research highlights NRAV as a potential therapeutic target for disrupting stemness pathways in liver cancer.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分=2.0分
business_impact
0.0分+0.0分=0.0分
scientific_rigor
1.5分+1.5分=3.0分
timeliness_innovation
1.5分+1.5分=3.0分
investment_perspective
2.5分+2.5分=5.0分
market_value_relevance
1.0分+1.0分=2.0分
team_institution_background
0.5分+0.5分=1.0分
technical_barrier_competition
1.0分+1.0分=2.0分
关键证据
NRAV is significantly overexpressed in HCC and associated with poor prognosis.
NRAV acts as a competing endogenous RNA (ceRNA) that sequesters let-7c-5p.
The NRAV-let-7c-5p-LIN28B axis enhances cancer stem cell marker expression.
真实性检查
否
AI评分总结
NRAV is identified as an m6A-modified long non-coding RNA that promotes stemness in hepatocellular carcinoma (HCC) through the let-7c-5p/LIN28B axis. The study demonstrates that NRAV enhances the expression of cancer stem cell markers and correlates with poor prognosis in HCC patients. By acting as a competing endogenous RNA, NRAV stabilizes LIN28B expression, linking RNA modifications to cancer stemness. This research highlights NRAV as a potential therapeutic target for disrupting stemness pathways in liver cancer.